PUMA BIOTECHNOLOGY INC

PBYI represents Puma Biotechnology, Inc., a biopharmaceutical company focused on the development and commercialization of innovative therapies for cancer patients. Its primary product is NERLYNX (neratinib), an oral tyrosine kinase inhibitor approved for extended adjuvant treatment of early-stage HER2-positive breast cancer and in combination for metastatic breast cancer. The company also conducts clinical trials for other oncology indications, making PBYI a commercial-stage biotech with both marketed drugs and a pipeline.

Investors track PBYI because it is a commercial-stage oncology company whose prospects hinge on clinical trial results, regulatory decisions, and sales of its flagship drug NERLYNX. Changes in prescription trends, pipeline updates, and competitive developments in the HER2-positive breast cancer space can influence sentiment. Additionally, PBYI's relatively small market capitalization means news can have an outsized effect on the shares, attracting both growth-oriented and event-driven investors.

PBYI has historically exhibited high volatility, which is common among small- and mid-cap biotechnology stocks. Its share price can react sharply to clinical trial data, FDA actions, quarterly earnings, and changes in reimbursement or competitive dynamics. Because the company's revenue is concentrated in a single marketed product, any news affecting NERLYNX or the broader oncology sector can amplify price swings. For the latest volatility readings, such as beta or implied volatility, please refer to the current data on this page.

Evaluating PBYI often involves both traditional and biotech-specific metrics. Since the company may have limited or uneven earnings, price-to-sales (P/S) and enterprise value-to-sales (EV/Sales) are commonly used. Investors also consider price-to-book (P/B) and cash flow measures. For pre-profit or transition periods, discounted cash flow models based on projected drug sales can be relevant. Compare these ratios to peers and consider pipeline potential, but rely on the latest PBYI financials shown on this page.

PBYI does not currently pay dividends. As a commercial-stage biopharmaceutical company, it likely reinvests earnings and cash flow into research, development, and commercialization of its products. Therefore, investors seeking regular income may not find PBYI suitable. For any future changes to the dividend policy, check the latest PBYI disclosures and the dividend information on this page.

Key risks for PBYI include heavy reliance on a single marketed product, NERLYNX, whose sales can be affected by competition, pricing pressure, and reimbursement changes. Clinical trial failures or regulatory delays for pipeline candidates could harm prospects. The company also faces the possibility of needing additional capital, which may dilute shareholders. Broader sector risks, such as shifts in healthcare policy or drug pricing reform, can add further uncertainty to the investment case.